• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

皮下注射胰高血糖素样肽-1(7-36)酰胺在非胰岛素依赖型糖尿病中的抗糖尿病作用机制

Mechanisms of the antidiabetic action of subcutaneous glucagon-like peptide-1(7-36)amide in non-insulin dependent diabetes mellitus.

作者信息

Schirra J, Leicht P, Hildebrand P, Beglinger C, Arnold R, Göke B, Katschinski M

机构信息

Department of Gastroenterology and Endocrinology, Philipps-University, Marburg, Germany.

出版信息

J Endocrinol. 1998 Jan;156(1):177-86. doi: 10.1677/joe.0.1560177.

DOI:10.1677/joe.0.1560177
PMID:9496247
Abstract

Twelve patients with non-insulin dependent diabetes mellitus (NIDDM) under secondary failure to sulfonylureas were studied to evaluate the effects of subcutaneous glucagon-like peptide-1(7-36)amide (GLP-1) on (a) the gastric emptying pattern of a solid meal (250 kcal) and (b) the glycemic and endocrine responses to this solid meal and an oral glucose tolerance test (OGTT, 300 kcal). 0.5 nmol/kg of GLP-1 or placebo were subcutaneously injected 20 min after meal ingestion. GLP-1 modified the pattern of gastric emptying by prolonging the time to reach maximal emptying velocity (lag period) which was followed by an acceleration in the post-lag period. The maximal emptying velocity and the emptying half-time remained unaltered. With both meals, GLP-1 diminished the postprandial glucose peak, and reduced the glycemic response during the first two postprandial hours by 54.5% (solid meal) and 32.7% (OGTT) (P < 0.05). GLP-1 markedly stimulated insulin secretion with an effect lasting for 105 min (solid meal) or 150 min (OGTT). The postprandial increase of plasma glucagon was abolished by GLP-1. GLP-1 diminished the postprandial release of pancreatic polypeptide. The initial and transient delay of gastric emptying, the enhancement of postprandial insulin release, and the inhibition of postprandial glucagon release were independent determinants (P < 0.002) of the postprandial glucose response after subcutaneous GLP-1. An inhibition of efferent vagal activity may contribute to the inhibitory effect of GLP-1 on gastric emptying.

摘要

对12例使用磺脲类药物继发失效的非胰岛素依赖型糖尿病(NIDDM)患者进行了研究,以评估皮下注射胰高血糖素样肽-1(7-36)酰胺(GLP-1)对以下方面的影响:(a)一顿固体餐(250千卡)的胃排空模式;(b)对这顿固体餐和口服葡萄糖耐量试验(OGTT,300千卡)的血糖和内分泌反应。进食后20分钟皮下注射0.5 nmol/kg的GLP-1或安慰剂。GLP-1通过延长达到最大排空速度的时间(延迟期)来改变胃排空模式,随后在延迟期后加速。最大排空速度和排空半衰期保持不变。对于两餐,GLP-1均降低了餐后血糖峰值,并使餐后前两小时的血糖反应分别降低了54.5%(固体餐)和32.7%(OGTT)(P<0.05)。GLP-1显著刺激胰岛素分泌,作用持续105分钟(固体餐)或150分钟(OGTT)。GLP-1消除了餐后血浆胰高血糖素的升高。GLP-1减少了餐后胰多肽的释放。皮下注射GLP-1后,胃排空的初始和短暂延迟、餐后胰岛素释放的增强以及餐后胰高血糖素释放的抑制是餐后血糖反应的独立决定因素(P<0.002)。传出迷走神经活动的抑制可能有助于GLP-1对胃排空的抑制作用。

相似文献

1
Mechanisms of the antidiabetic action of subcutaneous glucagon-like peptide-1(7-36)amide in non-insulin dependent diabetes mellitus.皮下注射胰高血糖素样肽-1(7-36)酰胺在非胰岛素依赖型糖尿病中的抗糖尿病作用机制
J Endocrinol. 1998 Jan;156(1):177-86. doi: 10.1677/joe.0.1560177.
2
Differential effects of subcutaneous GLP-1 on gastric emptying, antroduodenal motility, and pancreatic function in men.皮下注射胰高血糖素样肽-1对男性胃排空、十二指肠动力及胰腺功能的不同影响。
Proc Assoc Am Physicians. 1997 Jan;109(1):84-97.
3
Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM.皮下注射胰高血糖素样肽1(GLP-1 [7-36酰胺])对非胰岛素依赖型糖尿病患者的影响。
Diabetologia. 1996 Dec;39(12):1546-53. doi: 10.1007/s001250050613.
4
Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans.在健康人体中,胰高血糖素样肽1对胃排空的抑制作用超过其促胰岛素分泌作用。
Am J Physiol. 1997 Nov;273(5):E981-8. doi: 10.1152/ajpendo.1997.273.5.E981.
5
Erythromycin antagonizes the deceleration of gastric emptying by glucagon-like peptide 1 and unmasks its insulinotropic effect in healthy subjects.红霉素可拮抗胰高血糖素样肽1引起的胃排空减速,并在健康受试者中揭示其促胰岛素分泌作用。
Diabetes. 2005 Jul;54(7):2212-8. doi: 10.2337/diabetes.54.7.2212.
6
Glucagon-like peptide I enhances the insulinotropic effect of glibenclamide in NIDDM patients and in the perfused rat pancreas.胰高血糖素样肽I增强了格列本脲对非胰岛素依赖型糖尿病患者及灌注大鼠胰腺的促胰岛素分泌作用。
Diabetes Care. 1996 Aug;19(8):857-63. doi: 10.2337/diacare.19.8.857.
7
Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients.液体试验餐后的胃排空、葡萄糖反应及胰岛素分泌:外源性胰高血糖素样肽-1(GLP-1)-(7-36)酰胺对2型(非胰岛素依赖型)糖尿病患者的影响
J Clin Endocrinol Metab. 1996 Jan;81(1):327-32. doi: 10.1210/jcem.81.1.8550773.
8
Subcutaneous glucagon-like peptide-1 improves postprandial glycaemic control over a 3-week period in patients with early type 2 diabetes.皮下注射胰高血糖素样肽-1可改善早期2型糖尿病患者3周内的餐后血糖控制。
Clin Sci (Lond). 1998 Sep;95(3):325-9.
9
Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes.2型糖尿病患者静脉注射胰高血糖素样肽1后,固体餐后血糖浓度正常化及胃排空减速。
J Clin Endocrinol Metab. 2003 Jun;88(6):2719-25. doi: 10.1210/jc.2003-030049.
10
alpha-Glucosidase inhibition (acarbose) fails to enhance secretion of glucagon-like peptide 1 (7-36 amide) and to delay gastric emptying in Type 2 diabetic patients.α-葡萄糖苷酶抑制作用(阿卡波糖)未能增强2型糖尿病患者胰高血糖素样肽1(7-36酰胺)的分泌,也未能延迟胃排空。
Diabet Med. 2005 Apr;22(4):470-6. doi: 10.1111/j.1464-5491.2005.01451.x.

引用本文的文献

1
Glucose-Lowering Agents Developed in the Last Two Decades and Their Perioperative Implications.过去二十年研发的降糖药物及其围手术期影响
Pharmaceuticals (Basel). 2024 Dec 24;18(1):4. doi: 10.3390/ph18010004.
2
Rikkunshito increases peripheral incretin-hormone levels in humans and rats.理气和中汤可提高人和大鼠外周肠促胰岛素激素水平。
World J Methodol. 2024 Mar 20;14(1):88518. doi: 10.5662/wjm.v14.i1.88518.
3
Efficacy and safety of tirzepatide, dual GLP-1/GIP receptor agonists, in the management of type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials.
替尔泊肽(双重GLP-1/GIP受体激动剂)治疗2型糖尿病的疗效和安全性:一项随机对照试验的系统评价和荟萃分析
Diabetol Metab Syndr. 2023 Oct 30;15(1):222. doi: 10.1186/s13098-023-01198-4.
4
Impaired glucose tolerance is associated with enhanced postprandial pancreatic polypeptide secretion.糖耐量受损与餐后胰多肽分泌增强有关。
J Diabetes. 2022 May;14(5):334-344. doi: 10.1111/1753-0407.13268. Epub 2022 Apr 19.
5
Ultrasonographic assessment of the effect of metoclopramide, erythromycin, and exenatide on solid-phase gastric emptying in healthy cats.超声评估甲氧氯普胺、红霉素和艾塞那肽对健康猫固相胃排空的影响。
J Vet Intern Med. 2020 Jul;34(4):1440-1446. doi: 10.1111/jvim.15787. Epub 2020 Jun 8.
6
Liraglutide accelerates colonic transit in people with type 1 diabetes and polyneuropathy: A randomised, double-blind, placebo-controlled trial.利拉鲁肽可加速 1 型糖尿病合并多发性神经病患者的结肠传输:一项随机、双盲、安慰剂对照试验。
United European Gastroenterol J. 2020 Jul;8(6):695-704. doi: 10.1177/2050640620925968. Epub 2020 May 9.
7
LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept.LY3298176,一种新型双重 GIP 和 GLP-1 受体激动剂,用于治疗 2 型糖尿病:从发现到临床概念验证。
Mol Metab. 2018 Dec;18:3-14. doi: 10.1016/j.molmet.2018.09.009. Epub 2018 Oct 3.
8
Relationship Between Control of Glycemia and Gastric Emptying Disturbances in Diabetes Mellitus.糖尿病患者血糖控制与胃排空障碍之间的关系
Clin Gastroenterol Hepatol. 2016 Jul;14(7):929-36. doi: 10.1016/j.cgh.2015.11.021. Epub 2015 Dec 21.
9
Decreased gastric motility in type II diabetic patients.II型糖尿病患者胃动力下降。
Biomed Res Int. 2014;2014:894087. doi: 10.1155/2014/894087. Epub 2014 Jul 23.
10
Effect of Gongronema latifolium on gastric emptying in healthy dogs.宽叶楼梯草对健康犬胃排空的影响。
World J Gastroenterol. 2013 Feb 14;19(6):897-902. doi: 10.3748/wjg.v19.i6.897.